Qualiclinic Kft.

Budapest 33 trials 9 recruiting

33 Registered trials

9 Currently recruiting

Organisation

Qualiclinic Kft.

Location

Budapest, Hungary

Identifier

ORG-100043006

Address

Tuzer Utca 39, 1134, Hungary

Departments

-
#3103
2108
3103
40081
4013
Department of Rheumatology
HU10008
N/A
NA
Qualiclinic Egeszsegugyi Szolgaltato es Kutatasszervezo Kft.
Qualiclinic Kft.
Reumatologia
Rheumatology

Clinical trials at this site (33)

Search interface

A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in… Ended

2024-510826-16-00 Rheumatoid Arthritis 5 2025-04-07
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Moderate to Severe Rheumatoid Arthritis 4 2024-04-08
A study evaluating the effects of GLPG3667 given as oral treatment in adults with active systemic lupus erythematosus. Ended

2023-503183-16-00 Systemic Lupus Erythematosus 4 2024-01-16
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended

2023-503790-37-00 Post-Menopausal Osteoporosis 5 2024-01-09
A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is Ended

2022-501362-22-00 Psoriatic Arthritis 10 2023-04-18
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended

2022-501425-20-00 Rheumatoid Arthritis Arthritis Joint Diseases Muscul 4 2023-04-03
Study of efficacy, safety and tolerability of DFV890 in patients with knee osteoarthritis Ended

2023-507559-30-00 Knee Osteoarthritis 4 2021-11-09
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12